Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Parkinson's Disease

  Free Subscription

Articles published in J Biol Chem

Retrieve available abstracts of 15 articles:
HTML format

Single Articles

    October 2021
  1. GANDELMAN M, Dansithong W, Kales SC, Paul S, et al
    The AKT modulator A-443654 reduces alpha-synuclein expression and normalizes ER stress and autophagy.
    J Biol Chem. 2021;297:101191.
    PubMed     Abstract available

    July 2021
  2. PAN PY, Zhu J, Rizvi A, Zhu X, et al
    Synaptojanin1 deficiency upregulates basal autophagosome formation in astrocytes.
    J Biol Chem. 2021;297:100873.
    PubMed     Abstract available

    June 2021
  3. AMIREDDY N, Puttapaka SN, Vinnakota RL, Ravuri HG, et al
    Correction: The unintended mitochondrial uncoupling effects of the FDA-approved anti-helminth drug nitazoxanide mitigates experimental parkinsonism in mice.
    J Biol Chem. 2021;297:100864.

    January 2021
  4. WESTON LJ, Stackhouse TL, Spinelli KJ, Boutros SW, et al
    Genetic deletion of Polo-like kinase 2 reduces alpha-synuclein serine-129 phosphorylation in presynaptic terminals but not Lewy bodies.
    J Biol Chem. 2021;296:100273.
    PubMed     Abstract available

  5. RAMALINGAM N, Dettmer U
    Temperature is a key determinant of alpha- and beta-synuclein membrane interactions in neurons.
    J Biol Chem. 2021;296:100271.
    PubMed     Abstract available

    December 2020
  6. CLARK EH, Vazquez de la Torre A, Hoshikawa T, Briston T, et al
    Targeting mitophagy in Parkinson's disease.
    J Biol Chem. 2020 Dec 23:100209. doi: 10.1074/jbc.REV120.014294.
    PubMed     Abstract available

  7. CLARK EH, Vazquez de la Torre A, Hoshikawa T, Briston T, et al
    Targeting mitophagy in Parkinson's disease.
    J Biol Chem. 2020 Dec 18. pii: REV120.014294. doi: 10.1074/jbc.REV120.014294.
    PubMed     Abstract available

  8. GUINEY SJ, Adlard PA, Lei P, Mawal CH, et al
    Fibrillar alpha-synuclein toxicity depends on functional lysosomes.
    J Biol Chem. 2020;295:17497-17513.
    PubMed     Abstract available

    July 2020
  9. LAUTENSCHLAGER J, Wagner-Valladolid S, Stephens AD, Fernandez-Villegas A, et al
    Intramitochondrial proteostasis is directly coupled to alpha-synuclein and amyloid beta1-42 pathologies.
    J Biol Chem. 2020;295:10138-10152.
    PubMed     Abstract available

    May 2020
  10. LU J, Zhang S, Ma X, Jia C, et al
    Structural basis of the interplay between alpha-synuclein and Tau in regulating pathological amyloid aggregation.
    J Biol Chem. 2020;295:7470-7480.
    PubMed     Abstract available

    February 2020
  11. LEVY DR, Udgata A, Tourlomousis P, Symmons MF, et al
    Parkinson's disease-associated kinase LRRK2 regulates genes required for cell adhesion, polarization, and chemotaxis in activated murine macrophages.
    J Biol Chem. 2020 Feb 28. pii: RA119.011842. doi: 10.1074/jbc.RA119.011842.
    PubMed     Abstract available

    January 2020
  12. KUMARI R, Kumar R, Kumar S, Singh AK, et al
    Amyloid aggregates of the deubiquitinase OTUB1 are neurotoxic, suggesting that they contribute to the development of Parkinson's disease.
    J Biol Chem. 2020 Jan 31. pii: RA119.009546. doi: 10.1074/jbc.RA119.009546.
    PubMed     Abstract available

  13. FROULA JM, Castellana-Cruz M, Anabtawi NM, Camino JD, et al
    Correction: Defining alpha-synuclein species responsible for Parkinson's disease phenotypes in mice.
    J Biol Chem. 2020;295:1142.

    June 2019
  14. CHATTOPADHYAY M, Chowdhury AR, Feng T, Assenmacher CA, et al
    Mitochondrially targeted cytochrome P450 2D6 is involved in monomethylamine-induced neuronal damage in mouse models.
    J Biol Chem. 2019;294:10336-10348.
    PubMed     Abstract available

    April 2019
  15. PONZINI E, De Palma A, Cerboni L, Natalello A, et al
    Methionine oxidation in alpha-synuclein inhibits its propensity for ordered secondary structure.
    J Biol Chem. 2019;294:5657-5665.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.